A review of health care models for coronary heart disease interventions

Abstract

This article reviews models for the treatment of coronary heart disease (CHD). Whereas most of the models described were developed to assess the cost effectiveness of different treatment strategies, other models have also been used to extrapolate clinical trials, for capacity and resource planning, or to predict the future population with heart disease. In this paper we investigate the use of modelling techniques in relation to different types of health intervention, and we discuss the assumptions and limitations of these approaches. Many of the models reviewed in this paper use decision tree models for acute or short term interventions, and Markov or state transition models for chronic or long term interventions. Discrete event simulation has, however, been used for more complex whole system models, and for modelling resource-constrained interventions and operational planning. Nearly all of the studies in our review used cohort-based models rather than population based models, and therefore few models could estimate the likely total costs and benefits for a population group. Most studies used de novo purpose built models consisting of only a small number of health states. Models of the whole disease system were less common. The model descriptions were often incomplete. We recommend that the reporting of model structure, assumptions and input parameters is more explicit, to reduce the risk of biased reporting and ensure greater confidence in the model results.

Model-Based Economic Evaluation in Alzheimer's Disease: A Review of the Methods Available to Model Alzheimer's Disease Progression

“…Modelling methods have been used for many years to improve our understanding of a large number of health conditions, and to inform decision making. For example, modelling methods have been used in a variety of ways and settings to predict the risk of future cardiovascular events, based on known patient-level characteristics [5,6].…”

Contribution of Modeling Approaches and Virtual Populations in Transposing the Results of Clinical Trials into Real Life and in Enlightening Public Health Decisions

“…[18,19] One of the main advantages of DES is the simultaneous use of several functions or specific mathematical models for every studied event, taking into account complex and competitive situations. [20,21] JJ Caro used DES to estimate the public health interest of rimonabant in a French obese or overweighed diabetic population. [18] In this example, the characteristics of the virtual population were derived from French demographic data and from epidemiological studies monitoring of trends and determinants of cardiovascular diseases (MONICA), échantillon national témoin representatif des personnes diabétiques (representative national sample of people with diabetes in France or ENTRED) and étude de prise en charge du diabète de type 2 en France (study of management of type 2 diabetes in France or ECODIA).…”

Apport de la modélisation et des populations virtuelles pour transposer les résultats des essais cliniques à la vie réelle et éclairer la décision publique

“…[20,21] JJ Caro a utilisé l'approche DES pour estimer l'intérêt de Santé publique du rimonabant dans une population française diabétique obèse ou en surpoids. [18] Les caractéristiques de la population virtuelle étaient issues des données démographiques françaises, des études MONICA, l'étude Échantillon national témoin représentatif des personnes diabétiques (ENTRED) et l'étude prise en charge du diabète de type 2 en France (étude ECODIA).…”